NCT00536874View on ClinicalTrials.gov

Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

February 28, 2017

Conditions
Pancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles

DRUG

oxaliplatin

80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.

GENETIC

protein expression analysis

GENETIC

proteomic profiling

OTHER

diagnostic laboratory biomarker analysis

PROCEDURE

adjuvant therapy

PROCEDURE

neoadjuvant therapy

PROCEDURE

therapeutic conventional surgery

Trial Locations (1)

10065-0009

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00536874 - Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery | Biotech Hunter | Biotech Hunter